Experts are increasingly investigating retatrutide, a novel medication from Eli Lilly, as a potential step in body management. Different than many previous approaches, retatrutide is a dual -action agonist targeting both GLP-1 and GIP, hormones that affect appetite and blood glucose balance. Prelim